BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Bayer loses third appeals case over weedkiller


(Reuters) — Bayer lost a third appeal of U.S. court verdicts that awarded damages to customers blaming their cancers on the use of its glyphosate-based weedkillers, leaving the German drugs and pesticides group to pin hopes for legal relief on the U.S. Supreme Court.

A California appeals court late Monday upheld an $86 million verdict that found Bayer was responsible for a couple's cancer.

They had used Bayer's glyphosate-based Roundup product against weeds.

Bayer in February 2020 filed an appeal, saying the verdict could not be reconciled with sound science or with product clearance from the federal environmental regulator.

Roundup-related lawsuits have dogged the company since it acquired the brand as part of its $63 billion purchase of Monsanto in 2018.

Bayer reaffirmed plans to file a petition with the U.S. Supreme Court this month to review a similar Roundup case that went in favor of Roundup user Edwin Hardeman.

Bayer struck a settlement deal in principle with plaintiffs last year. But it failed to win court approval for a separate agreement on how to handle future cases.

Bayer has indicated it intends to keep the product on the market.

Among measures to contain the legal damage, it plans to replace glyphosate in weedkillers for the U.S. residential market with other active ingredients.

It will continue to sell the herbicide to farmers.


Read Next

  • $25M Roundup verdict upheld in blow to Bayer

    (Reuters) — A federal appeals court Friday upheld a $25 million judgment and trial verdict finding Bayer's Roundup caused a California resident's non-Hodgkin lymphoma, dealing a blow to the chemical company’s hopes of limiting its legal risk over the weed-killer.